Multiple myeloma (MM) is a disease of the elderly, with a median age of 70 years at the time of first diagnosis. Only 13.4% of the newly diagnosed MM patients receive an ASCT as part of their first-line treatment of MM because of age of presentation and co-morbidities. Therefore, the majority of newly diagnosed MM patients fall under the non-transplant and is cared for by community hematologists and oncologists. About 15-20% of MM is categorized as high-risk MM (HRMM) based on their aggressive nature and shorter survival. There is no standard of care therapy for non-transplant HRMM patients. The SWOG 1211 is the first national effort attempting to establish standard of care therapy for the non-transplant HRMM patients - the data will have broader impact on how this subgroups is treated out in the community. The current proposal is an ancillary study to the S1211 trial; it wil evaluate the use of PET-CT in predicting prognosis in non-transplant HRMM patients. The addition of this ancillary proposal to the parent study will be timely, enhance the knowledge about the use of PET-CT as a prognostic tool for non-transplant HRMM, and practice changing.
Multiple myeloma is an incurable, yet controllable blood cancer. About 20% of newly diagnosed myeloma patients have a very high risk of disease relapse and mortality within the first 2 years of diagnosis. The SWOG 1211 clinical trial is the first national study design for newly diagnosed high risk myeloma patients. In the proposed project, the investigators will evaluate the use of PET-CT scans in early identification patients who might have disease relapse.
| Usmani, Saad Z; Seifter, Eric (2018) Treatment approach for young, fit, newly diagnosed multiple myeloma patients. Hematology Am Soc Hematol Educ Program 2018:97-102 |
| Usmani, S Z; Sexton, R; Ailawadhi, S et al. (2015) Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. Blood Cancer J 5:e334 |
